Company profile: Aeglea BioTherapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage enzyme therapies for rare metabolic diseases and investigational monoclonal antibody programs for IBD, including SPY001 targeting α4β7 integrin and SPY002 targeting TL1A, with rational combination studies (SPY120, SPY130, SPY230) and precision immunology approaches using genetic or biomarker-based patient selection.
Products and services
- Rational Combinations: Architects pre-clinical and planned clinical studies combining monoclonal antibodies for IBD treatment, evaluating synergy across SPY120, SPY130, and SPY230 programs
- SPY002: Produces a high-potency monoclonal antibody that binds tumor necrosis factor-like ligand 1A (TL1A) with high selectivity, explicitly developed for potent, selective target engagement
- SPY001: Engineers a high-selectivity monoclonal antibody targeting the α4β7 integrin, designed for high potency to achieve precise binding and robust target-specific activity
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Aeglea BioTherapeutics
Cydan
HQ: United States
Website
- Description: Provider of orphan drug accelerator services focused on identifying and de-risking compounds with therapeutic and commercial potential.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cydan company profile →
Som Pharmaceuticals
HQ: Switzerland
Website
- Description: Provider of novel anti-tumour somatostatin analogue (SSA) peptide medicines and diagnostics for patients with rare diseases that have unmet medical needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Som Pharmaceuticals company profile →
Imegen
HQ: Spain
Website
- Description: Provider of biomedical services and products for genetic analysis, offering diagnostic, prognostic, and preventive genetic services to improve health and quality of life, with the aim of being a worldwide reference in human genetics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Imegen company profile →
Mitobridge
HQ: United States
Website
- Description: Provider of small molecule therapeutics that improve mitochondrial function to address diseases with high unmet need. Pipeline includes investigational candidates: ASP0367 for primary mitochondrial myopathies and Duchenne muscular dystrophy, ASP1128 for acute kidney injury, and an NAD+ modulation program targeting aging-related conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mitobridge company profile →
Lumos Pharma
HQ: United States
Website
- Description: Provider of biopharmaceutical programs developing a novel treatment for Creatine Transporter Deficiency and LUM-201 for Pediatric Growth Hormone Deficiency, an oral small molecule that stimulates growth hormone secretion from the pituitary; supporting the OraGrowtH210 Phase 2 and OraGrowtH212 PK/PD studies, a Predictive Enrichment Markers strategy to identify responders, and an Expanded Access/Compassionate Use program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lumos Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Aeglea BioTherapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Aeglea BioTherapeutics
2.2 - Growth funds investing in similar companies to Aeglea BioTherapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Aeglea BioTherapeutics
4.2 - Public trading comparable groups for Aeglea BioTherapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →